In a TCGA study characterizing the molecular landscape of urothelial bladder carcinoma, a p53 mutation rate of 49% was recorded in the samples tested [56], drawing a similarity to the common observation of p53 mutation in BL-CL cells. The gene discussed is TP53; the disease is bladder transitional cell carcinoma.